Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Drug design

Designing drugs with reversible activity

Nature Biotechnology (2024)Cite this article

Subjects

A strategy for creating drugs that can be quickly neutralized is demonstrated for anticoagulants.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schematic representation of DNA and PNA derivatives and their pharmaceutical applications.

References

  1. Dockerill, M. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02209-z (2024).

    Article  Google Scholar 

  2. Hirsh, J., Anand, S. S., Halperin, J. L. & Fuster, V. Circulation 103, 2994–3018 (2001).

    Article  CAS  PubMed  Google Scholar 

  3. Brenner, S. & Lerner, R. A. Proc. Natl Acad. Sci. USA 89, 5381–5383 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Melkko, S., Scheuermann, J., Dumelin, C. E. & Neri, D. Nat. Biotechnol. 22, 568–574 (2004).

    Article  CAS  PubMed  Google Scholar 

  5. Mannocci, L. et al. Proc. Natl Acad. Sci. USA 105, 17670–17675 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gartner, Z. J. et al. Science 305, 1601–1605 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Clark, M. A. et al. Nat. Chem. Biol. 5, 647–654 (2009).

    Article  CAS  PubMed  Google Scholar 

  8. Barluenga, S. & Winssinger, N. Acc. Chem. Res. 48, 1319–1331 (2015).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Philogen SpA, Siena, Italy

    Dario Neri

  2. ETH Zürich, Zurich, Switzerland

    Dario Neri

Authors
  1. Dario Neri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dario Neri.

Ethics declarations

Competing interests

D.N. is co-founder, CEO and shareholder of Philogen, a biotech company that works (among other things) in the field of DNA-encoded chemical libraries.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neri, D. Designing drugs with reversible activity. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02242-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41587-024-02242-y

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research